CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Abstract Text:

Background A 63-year-old female presented to her primary physician with numbness and weakness in her left leg, which progressed over several days to involve her entire lower extremities. MRI of the spine and brain revealed multiple metastases. The patient received ipilimumab and after 3 months experienced intermittent confusion and focal seizures.Investigations Electroencephalogram and MRI scans of the spine and brain, followed by surgical removal of a left frontal cortical brain metastasis and subsequent histological and pathological analyses.Diagnosis Metastatic melanoma from an unknown primary tumor.Management The patient was treated with ipilimumab on a compassionate-use program and dexamethasone, celecoxib, and levetiracetam to treat the symptoms and seizures. Postoperative stereotactic radiosurgery was initiated.

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Nature clinical practice. Oncology

VOLUME: 5

Page Numbers: 557-61

Journal Abbreviation:

ISSN: 1743-4262

DAY: 29

MONTH: 07

YEAR: 2008

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101226509

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

AFFILIATION: FS Hodi is Clinical Director of the Melanoma Program at the Dana-Farber Cancer Institute, Boston, MA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Nat Clin Pract Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS Related Publications

• A unique microvascular phenotype shared by juvenile hemangiomas and human placenta.
• Apocrine cystadenoma and apocrine hidrocystoma: examination of 21 cases with emphasis on nomenclature according to proliferative features.
• CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
• Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma.
• Frequency of dysplastic nevi among nevomelanocytic lesions submitted for histopathologic examination. Time trends over a 37-year period.
• Infantile hemangioma: clinical resolution with 5% imiquimod cream.
• Interface dermatitis.
• Investigation of the vitamins A and E and beta-carotene content in milk from UK organic and conventional dairy farms.
• Linear IgA bullous dermatosis v dermatitis herpetiformis. Quantitative measurements of dermoepidermal alterations.
• Melanocytic proliferations associated with lichen sclerosus.
• Microvascular injury in lymphomatoid granulomatosis involving the skin. An ultrastructural study.
• Multiple melanocytoma.
• Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy.
• Oral warty dyskeratoma.
• Origin of cutaneous melanoma in a congenital dysplastic nevus spilus.
• The molecular basis of melanomagenesis and the metastatic phenotype.
• The nonrandom distribution of facial hemangiomas.
• The precursors of malignant melanoma.
• Unusual histologic and clinical variants of melanoma: implications for therapy.
• Vulvar nevi, lichen sclerosus et atrophicus, and vitiligo.